Streetbeat News

Regulatory

VTGN

Vistagen (NASDAQ:VTGN) has reported new preclinical data supporting the potential antidepressant activity of its Itruvone nasal spray. The study showed that the spray binds to receptors of peripheral chemosensory neurons in the nasal cavity, limiting transport of molecules to the circulatory system and minimizing potential systemic exposure. The company believes this could change the treatment paradigm for depression disorders. Vistagen recently reported that Itruvone is now staged for potential Phase 2B clinical development in the U.S. as a stand-alone treatment for major depressive disorder (MDD).

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 12:08 pm

AMAT

LRCX

NVDA

Chinese chip equipment makers Advanced Micro-Fabrication Equipment Inc and Naura Technology Group Co expect to double their profits due to the U.S. tech embargo forcing manufacturers to seek domestic alternatives. However, their stocks dropped after recent Chinese economic data missed estimates. Meanwhile, the embargo has created an underground market for chips, with vendors in Shenzhen claiming the availability of Nvidia Corp's A100 AI chips at double the usual price.

Portfolio Pulse from Anusuya Lahiri

July 17, 2023 | 12:06 pm

PDSB

PDS Biotechnology Corporation (NASDAQ:PDSB) announced that an abstract on interim data from a clinical trial evaluating the combination of PDS0301, an IL-12-based immunocytokine, with the chemotherapy medication docetaxel has been accepted for oral presentation at the 11th Annual Meeting of the International Cytokine & Interferon Society (Cytokines 2023). The trial is investigating the safety, immune responses and clinical activity of PDS0301 and docetaxel in metastatic castration-sensitive and castration-resistant prostate cancer patients.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 12:05 pm

MDGL

Madrigal Pharmaceuticals has completed the rolling submission of its New Drug Application (NDA) to the FDA for Resmetirom, a treatment for NASH with liver fibrosis. The company has requested a priority review of the application.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 12:03 pm

JANX

Janux Therapeutics has announced interim clinical data from its Phase 1a dose escalation for PSMA-TRACTr JANX007 and an update on pipeline programs. The preliminary data showed encouraging safety results with no dose-limiting toxicities. The company will host a virtual investor event today at 4:00 PM Eastern Time.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 12:02 pm

INTC

NVDA

QCOM

TSM

CEOs of Intel Corp and Qualcomm Inc are set to visit Washington to discuss China policy, including market conditions, export controls, and other matters affecting their businesses. U.S. officials are considering strengthening export rules affecting high-performance computing chips and shipments to Huawei Technologies Co Ltd, which could impact Intel and Qualcomm. The potential rule tightening could also significantly affect Nvidia Corp. The executives aim to explain to government officials the repercussions of further stricter embargo on the Chinese semiconductor industry.

Portfolio Pulse from Anusuya Lahiri

July 17, 2023 | 11:59 am

MIRM

Trading of Mirum Pharmaceuticals' shares has been temporarily halted due to pending news.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 11:56 am

MRAI

Marpai, Inc. has regained compliance with Nasdaq's minimum bid price requirement. The company's Class A common stock had a closing bid price of $1.00 per share or greater for the last 10 consecutive business days, from June 29, 2023 to July 13, 2023.

Portfolio Pulse from Charles Gross

July 17, 2023 | 11:28 am

BIVI

Biovie has announced data from a Phase 2 exploratory biomarker study, detailing the epigenetic basis for how its NE3107 may have potentially regulated specific genes. This regulation is significantly correlated with observed cognitive and biomarker improvements.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 11:16 am

VIRI

Virios Therapeutics has announced data showing improvement in multiple long-Covid symptoms following treatment with a combination of Valacyclovir and Celecoxib. The data comes from an exploratory, open-label, proof of concept study.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 11:10 am